Artiva Biotherapeutics, Inc. (Nasdaq:
ARTV), a clinical-stage biotech company, appointed Thad Huston as CFO effective February 18, 2026.1245
Huston, 56, has over 30 years of experience in finance, commercial strategy, business development, and operations at companies like Galapagos, Kite Pharma, LivaNova, and Johnson & Johnson.1234
Compensation includes $540,000 annual base salary, 40% target bonus, and 220,000 RSUs vesting over four years starting February 15, 2027.245
Announcement made February 24, 2026; shares traded at $4.68, down 2.33% pre-market.14
Sources:
1. https://www.nasdaq.com/articles/artiva-biotherapeutics-names-thad-huston-cfo
2. https://www.investing.com/news/sec-filings/artiva-biotherapeutics-appoints-thad-huston-as-chief-financial-officer-93CH-4523060
3. https://www.marketscreener.com/news/artiva-biotherapeutics-inc-announces-appointment-of-thad-huston-as-chief-financial-officer-ce7e5cdbdb8df521
4. https://www.biospace.com/press-releases/artiva-biotherapeutics-announces-appointment-of-thad-huston-as-chief-financial-officer-and-award-of-inducement-grant
5. https://www.stocktitan.net/sec-filings/ARTV/8-k-artiva-biotherapeutics-inc-reports-material-event-6380ff6c95f7.html